Home
    Welcome Note
    Registration
    Accommodation
    Contact Us
     Home
     Welcome Note
     Congress Chairpersons
     Committees
     Faculty
     Timetable
     Scientific Program
         Congress Presentations
     Leukemia Supplements
     Abstract Submission
         Poster Presentations
         Poster Guidelines
     CME Accreditation
         CME - EACCME
         EHA - CME
     Registration
         Invitation Letter
     Accommodation
         Andel’s Hotel Berlin
     Sponsorship & Exhibition
         Sponsors
         Exhibitors
     General Information
         Before You Travel...
         Tips and Hints
         Italian Agent
     About Berlin
     Endorsement
     Partners
  
The International Congress on
Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)
Andel’s Hotel, Berlin, Germany, September 8-11, 2011
 
  Congress Presentations Print
 
Friday, September 9, 2011
 
Session 1: SCT in Myeloma and MDS
Autologous SCT as first line treatment?
Yes: J.L. Harousseau, France
No: J. Blade, Spain

Allo SCT in elderly patients (>60 y) with MDS
Yes: N. Kröger, Germany
 
Session 2: Relapse Prevention
Can we prevent relapse by novel conditioning regimen?
Yes: M. de Lima, USA
No: A. Shimoni , Israel
 
Special Debate: Is there any place for the prophylactic collection of autologous stem cells for major radiation incidents?
Yes: A.S. Shimosaka, Japan
No: D.M. Weinstock, USA
Yes: R. Powles, UK
 
Session 3: AML and CML
Indication for unrelated allo SCT in 1. CR AML
No: I. Yakoub-Agha, France

Allogeneic SCT for CML after failure to 1. TKI
Yes: E. Olavarria, Spain
No: J.F. Apperley, UK
 
Session 4: Treatment and Prevention of Relapse
Second allo for relaps
No: S.A. Giralt, USA

Donor selection to prevent relapse
According to KIR typing: J. Miller, USA
 
Session 5: Aplastic Anemia and Autoimmune Diseases
Autologous SCT for autoimmune diseas
Yes: D. Farge-Bancel, France
No: S. Dabadghao, India
 
Session 6: Refractory and Residual Leukemia
Allo SCT for refractory leukemia
No: D. Blaise, France

Should all MRD positive patients receive allo SCT?
Yes: P. Bader, Germany
No: G. Henze, Germany
 
Session 7: GvHD Prevention by T-Cell Modulation
Can Treg prevent GvHD without losing GvL?
Yes: M.F. Martelli, Italy
No: J.L. Ferrara, USA

Is photopheresis treatment of choice for cGvHD?
Yes: H. Greinix, Austria
No: G. Socié, France

 
Saturday, September 10, 2011
 
Session 8: Cord Blood
Is double cord blood to be preferred to a single unit?
No: V. Rocha, France
 
Should cord blood unit be selected according to HLA or cell-based?
Cell-based: E. Gluckman, France
 
Session 9: Myelofibrosis and Haploidentical Transplantation
Allo SCT for elderly myelofibrosis patients (>60 y)
Yes: N. Kröger, Germany
No: R.A. Mesa, USA

Should haplo-SCT be performed with T-cell depletion?
Yes: R. Handgretinger, Germany
No: F. Ciceri, Italy
 
Session 10: Donor Selection
Which is the donor of choice if no MUD is available?
Cord blood: W. Arcese, Italy

Should we expand cord blood?
No: V. Rocha, France
 
Novartis Satellite Symposium
Update and Perspectives on Iron Chelation and Immunotherapy in Transplantation
Pathophysiology of Acute GvHD: Innate Meets Adaptive Immunity: E. Holler, Regensburg
Does Iron Chelation Improve Survival in SCT? H. Al-Ali, Leipzig
Practical Aspects of an Iron Chelation Therapy in SCT: U. Platzbecker, Dresden
 
Session 11: Cell and Gene Therapy
Is specific T-cell therapy targeting mHag useful?
Yes: S. Riddell, USA
No: M. Bornhäuser, Germany

Gene therapy for genetic diseases (SCID, FA, CGD)
No: I. Müller, Germany
 
Session 12: Lymphoma
Autologous SCT in FL
Yes: C. Gisselbrecht, France
No: U. Dührsen, Germany

Transplantation for T-cell lymphoma
Pro auto: P. Reimer, Germany
 
Session 13: T-Cell Depletion and Mesenchymal Stroma Cells
T-cell depletion and T-cell add back
Yes: J.H.F Falkenburg, The Netherlands
No: R. Storb, USA

MSC for GvHD
Yes: K. Le Blanc, Sweden
No: F. Locatelli, Italy
 
Session 14: Allogeneic SCT for Myeloma and Hodgkin's Disease
Is there a place for allo SCT in Hodgkin’s disease?
No: V. Diehl, Germany
 
Session 15: GvHD Prevention by Antibodies
GvHD prevention
Pro Alemtuzemab: S. Mackinnon, UK

Is it possible to separate GvHD from GvL?
Yes: E. Holler, Germany

Sunday, September 11, 2011
Session 16: Improving Transplant Outcome in Multiple Myeloma
Should CR be target of therapy in MM?
Yes: S.A. Giralt, USA

No: B. Barlogie, USA

 
Should CR be target of therapy in MM?
Pro consolidation: J. Blade, Spain

 
Session 17: Infection
Should CMV infection post allo SCT be treated by cell-based therapy?
No: P. Ljungman, Sweden
 
Is combined antifungal therapy more efficient than single agent therapy?
Yes: N. Keller, Israel
No: G. Maschmeyer, Germany

 
Session 18: Fungal Resistance
Aspergillus resistance is only seen on the petri dish and not in the patient
Con: G. Maschmeyer, Germany
 
Session 19: ALL and Intensity of Conditioning Regimen
Reduced or standard conditioning?
Pro reduced: R. Storb, USA

 
 

Home    Contact Us   
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 06/26/2013 Created by     WebStudio.co.il